Listening to the call, there will be no futility analysis, so that's not an issue--only the final survival data. I wonder why this is no longer needed? Maybe because they are so close to the conclusion of the trial and if they have a subset of long term survivors, a futility analysis isn't needed? In other words, the company, monitoring board and FDA do want to give every chance to see a survival benefit.
News 
Market Data 
Discover 
